Claims for Patent: 6,087,340

Summary for Patent: 6,087,340

Title:	Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
Abstract:	A sealed glass container containing therein a stable, injectable, sterile, pyrogen-free doxorubicin anti-tumor composition in a solution which consists essentially of a physiologically acceptable salt of doxorubicin dissolved in a physiologically acceptable solvent therefor, wherein said solution has not been reconstituted from a lyophilizate, and wherein said solution has a pH of from 2.5-3.5 and a concentration of said doxorubicin of from 0.1 to 100 mg/ml.
Inventor(s):	Gatti; Gaetano (Milan, IT), Oldani; Diego (Milan, IT), Bottoni; Giuseppe (Borgamo, IT), Confalonieri; Carlo (Milan, IT), Gambini; Luciano (Milan, IT), De Ponti; Roberto (Milan, IT)
Assignee:	Pharmacia & Upjohn, Inc. (Kalmazoo, MI)
Application Number:	09/149,381
Patent Claims:	1. A physiologically acceptable solution of epirubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, tartaric acid, acetic acid, succinic acid, ascorbic acid, citric acid, and glutamic acid and the concentration of said epirubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution has not been reconstituted from a lyophilizate. 2. The solution of claim 1 wherein the physiologically acceptable solvent is selected from the group consisting of water, ethanol, polyethylene glycol, dimethyl acetamide, and mixtures thereof. 3. The solution of claim 1 wherein the physiologically acceptable solvent is water. 4. The solution of claim 1 further comprising a tonicity adjusting agent. 5. The solution of claim 1 wherein the concentration of epirubicin hydrochloride is from 0.1 to 50 mg/ml. 6. The solution of claim 1 wherein the concentration of epirubicin hydrochloride is from 1 to 20 mg/ml. 7. The solution of claim 1 wherein the pH of said solution is from about 2.7 to about 3.3. 8. The solution of claim 1 wherein said physiologically acceptable solvent is a saline solution. 9. The solution of claim 1 wherein said physiologically acceptable solvent is a dextrose solution. 10. The solution of claim 1 wherein said physiologically acceptable solvent is sterile water. 11. A physiologically acceptable aqueous solution of epirubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid and the concentration of said epirubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution has not been reconstituted from a lyophilizate. 12. A physiologically acceptable solution of epirubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, tartaric acid, and acetic acid and the concentration of said epirubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution has not been reconstituted from a lyophilizate. 13. A storage stable physiologically acceptable aqueous solution of epirubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from about 2.7 to about 3.3 with a physiologically acceptable acid and the concentration of said epirubicin hydrochloride being from 0.1 to 100 mg/ml. 14. A storage stable physiologically acceptable solution of epirubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from about 2.7 to 3.3 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, tartaric acid and acetic acid and the concentration of said epirubicin hydrochloride being from 0.1 to 100 mg/ml. 15. A physiologically acceptable solution of epirubicin hydrochloride dissolved in a physiologically acceptable aqueous solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, tartaric acid, acetic acid, succinic acid, ascorbic acid, citric acid, and glutamic acid and the concentration of said epirubicin hydrochloride being from 0.1 to 100 mg/ml. 16. The solution of claim 15 further comprising a tonicity adjusting agent. 17. The solution of claim 15 wherein the concentration of epirubicin hydrochloride is from 0.1 to 50 mg/ml. 18. The solution of claim 15 wherein the concentration of epirubicin hydrochloride is from 1 to 20 mg/ml. 19. The solution of claim 15 wherein the pH of said solution is from about 2.7 to about 3.3. 20. The solution of claim 15 wherein said physiologically acceptable solvent is a saline solution. 21. The solution of claim 15 wherein said physiologically acceptable solvent is a dextrose solution. 22. The solution of claim 15 wherein said physiologically acceptable solvent is sterile water. 23. A physiologically acceptable solution of epirubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, and tartaric acid, the concentration of said epirubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution is in a sealed container and has not been reconstituted from a lyophilizate in said container.

Details for Patent 6,087,340

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2005-08-02